The global market for Obstetrics and Gynecology Drugs was valued at US$ 18390 million in the year 2024 and is projected to reach a revised size of US$ 30300 million by 2031, growing at a CAGR of 7.5% during the forecast period.

Obstetrics and Gynecology Drugs Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Obstetrics and Gynecology Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Obstetrics and Gynecology Drugs.

The Obstetrics and Gynecology Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Obstetrics and Gynecology Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Obstetrics and Gynecology Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Obstetrics and Gynecology Drugs Market Report

Report Metric	Details
Report Name	Obstetrics and Gynecology Drugs Market
Accounted market size in year	US$ 18390 million
Forecasted market size in 2031	US$ 30300 million
CAGR	7.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Hormonal Therapy Non-Hormonal Therapy
Segment by Application	Hospital Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Merck, Eli Lilly, Amgen, Roche, AstraZeneca, Bayer, Abbott, Abbvie, GlaxoSmithKline, Novartis, Lupin, Johnson & Johnson, Ferring, TherapeuticsMD
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Obstetrics and Gynecology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Obstetrics and Gynecology Drugs Market growing?

Ans: The Obstetrics and Gynecology Drugs Market witnessing a CAGR of 7.5% during the forecast period 2025-2031.

What is the Obstetrics and Gynecology Drugs Market size in 2031?

Ans: The Obstetrics and Gynecology Drugs Market size in 2031 will be US$ 30300 million.

Who are the main players in the Obstetrics and Gynecology Drugs Market report?

Ans: The main players in the Obstetrics and Gynecology Drugs Market are Pfizer, Merck, Eli Lilly, Amgen, Roche, AstraZeneca, Bayer, Abbott, Abbvie, GlaxoSmithKline, Novartis, Lupin, Johnson & Johnson, Ferring, TherapeuticsMD

What are the Application segmentation covered in the Obstetrics and Gynecology Drugs Market report?

Ans: The Applications covered in the Obstetrics and Gynecology Drugs Market report are Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Obstetrics and Gynecology Drugs Market report?

Ans: The Types covered in the Obstetrics and Gynecology Drugs Market report are Hormonal Therapy, Non-Hormonal Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Hormonal Therapy

1.2.3 Non-Hormonal Therapy

1.3 Market by Application

1.3.1 Global Obstetrics and Gynecology Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Obstetrics and Gynecology Drugs Market Perspective (2020-2031)

2.2 Global Obstetrics and Gynecology Drugs Growth Trends by Region

2.2.1 Global Obstetrics and Gynecology Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Obstetrics and Gynecology Drugs Historic Market Size by Region (2020-2025)

2.2.3 Obstetrics and Gynecology Drugs Forecasted Market Size by Region (2026-2031)

2.3 Obstetrics and Gynecology Drugs Market Dynamics

2.3.1 Obstetrics and Gynecology Drugs Industry Trends

2.3.2 Obstetrics and Gynecology Drugs Market Drivers

2.3.3 Obstetrics and Gynecology Drugs Market Challenges

2.3.4 Obstetrics and Gynecology Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Obstetrics and Gynecology Drugs Players by Revenue

3.1.1 Global Top Obstetrics and Gynecology Drugs Players by Revenue (2020-2025)

3.1.2 Global Obstetrics and Gynecology Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Obstetrics and Gynecology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Obstetrics and Gynecology Drugs Revenue

3.4 Global Obstetrics and Gynecology Drugs Market Concentration Ratio

3.4.1 Global Obstetrics and Gynecology Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Obstetrics and Gynecology Drugs Revenue in 2024

3.5 Global Key Players of Obstetrics and Gynecology Drugs Head office and Area Served

3.6 Global Key Players of Obstetrics and Gynecology Drugs, Product and Application

3.7 Global Key Players of Obstetrics and Gynecology Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Obstetrics and Gynecology Drugs Breakdown Data by Type

4.1 Global Obstetrics and Gynecology Drugs Historic Market Size by Type (2020-2025)

4.2 Global Obstetrics and Gynecology Drugs Forecasted Market Size by Type (2026-2031)

5 Obstetrics and Gynecology Drugs Breakdown Data by Application

5.1 Global Obstetrics and Gynecology Drugs Historic Market Size by Application (2020-2025)

5.2 Global Obstetrics and Gynecology Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Obstetrics and Gynecology Drugs Market Size (2020-2031)

6.2 North America Obstetrics and Gynecology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Obstetrics and Gynecology Drugs Market Size by Country (2020-2025)

6.4 North America Obstetrics and Gynecology Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Obstetrics and Gynecology Drugs Market Size (2020-2031)

7.2 Europe Obstetrics and Gynecology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Obstetrics and Gynecology Drugs Market Size by Country (2020-2025)

7.4 Europe Obstetrics and Gynecology Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Obstetrics and Gynecology Drugs Market Size (2020-2031)

8.2 Asia-Pacific Obstetrics and Gynecology Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Obstetrics and Gynecology Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Obstetrics and Gynecology Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Obstetrics and Gynecology Drugs Market Size (2020-2031)

9.2 Latin America Obstetrics and Gynecology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Obstetrics and Gynecology Drugs Market Size by Country (2020-2025)

9.4 Latin America Obstetrics and Gynecology Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Obstetrics and Gynecology Drugs Market Size (2020-2031)

10.2 Middle East & Africa Obstetrics and Gynecology Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Obstetrics and Gynecology Drugs Introduction

11.1.4 Pfizer Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Merck

11.2.1 Merck Company Details

11.2.2 Merck Business Overview

11.2.3 Merck Obstetrics and Gynecology Drugs Introduction

11.2.4 Merck Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.2.5 Merck Recent Development

11.3 Eli Lilly

11.3.1 Eli Lilly Company Details

11.3.2 Eli Lilly Business Overview

11.3.3 Eli Lilly Obstetrics and Gynecology Drugs Introduction

11.3.4 Eli Lilly Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.3.5 Eli Lilly Recent Development

11.4 Amgen

11.4.1 Amgen Company Details

11.4.2 Amgen Business Overview

11.4.3 Amgen Obstetrics and Gynecology Drugs Introduction

11.4.4 Amgen Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.4.5 Amgen Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Obstetrics and Gynecology Drugs Introduction

11.5.4 Roche Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.5.5 Roche Recent Development

11.6 AstraZeneca

11.6.1 AstraZeneca Company Details

11.6.2 AstraZeneca Business Overview

11.6.3 AstraZeneca Obstetrics and Gynecology Drugs Introduction

11.6.4 AstraZeneca Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.6.5 AstraZeneca Recent Development

11.7 Bayer

11.7.1 Bayer Company Details

11.7.2 Bayer Business Overview

11.7.3 Bayer Obstetrics and Gynecology Drugs Introduction

11.7.4 Bayer Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.7.5 Bayer Recent Development

11.8 Abbott

11.8.1 Abbott Company Details

11.8.2 Abbott Business Overview

11.8.3 Abbott Obstetrics and Gynecology Drugs Introduction

11.8.4 Abbott Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.8.5 Abbott Recent Development

11.9 Abbvie

11.9.1 Abbvie Company Details

11.9.2 Abbvie Business Overview

11.9.3 Abbvie Obstetrics and Gynecology Drugs Introduction

11.9.4 Abbvie Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.9.5 Abbvie Recent Development

11.10 GlaxoSmithKline

11.10.1 GlaxoSmithKline Company Details

11.10.2 GlaxoSmithKline Business Overview

11.10.3 GlaxoSmithKline Obstetrics and Gynecology Drugs Introduction

11.10.4 GlaxoSmithKline Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.10.5 GlaxoSmithKline Recent Development

11.11 Novartis

11.11.1 Novartis Company Details

11.11.2 Novartis Business Overview

11.11.3 Novartis Obstetrics and Gynecology Drugs Introduction

11.11.4 Novartis Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.11.5 Novartis Recent Development

11.12 Lupin

11.12.1 Lupin Company Details

11.12.2 Lupin Business Overview

11.12.3 Lupin Obstetrics and Gynecology Drugs Introduction

11.12.4 Lupin Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.12.5 Lupin Recent Development

11.13 Johnson & Johnson

11.13.1 Johnson & Johnson Company Details

11.13.2 Johnson & Johnson Business Overview

11.13.3 Johnson & Johnson Obstetrics and Gynecology Drugs Introduction

11.13.4 Johnson & Johnson Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.13.5 Johnson & Johnson Recent Development

11.14 Ferring

11.14.1 Ferring Company Details

11.14.2 Ferring Business Overview

11.14.3 Ferring Obstetrics and Gynecology Drugs Introduction

11.14.4 Ferring Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.14.5 Ferring Recent Development

11.15 TherapeuticsMD

11.15.1 TherapeuticsMD Company Details

11.15.2 TherapeuticsMD Business Overview

11.15.3 TherapeuticsMD Obstetrics and Gynecology Drugs Introduction

11.15.4 TherapeuticsMD Revenue in Obstetrics and Gynecology Drugs Business (2020-2025)

11.15.5 TherapeuticsMD Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Obstetrics and Gynecology Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Hormonal Therapy

Table 3. Key Players of Non-Hormonal Therapy

Table 4. Global Obstetrics and Gynecology Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Obstetrics and Gynecology Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Obstetrics and Gynecology Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Obstetrics and Gynecology Drugs Market Share by Region (2020-2025)

Table 8. Global Obstetrics and Gynecology Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Obstetrics and Gynecology Drugs Market Share by Region (2026-2031)

Table 10. Obstetrics and Gynecology Drugs Market Trends

Table 11. Obstetrics and Gynecology Drugs Market Drivers

Table 12. Obstetrics and Gynecology Drugs Market Challenges

Table 13. Obstetrics and Gynecology Drugs Market Restraints

Table 14. Global Obstetrics and Gynecology Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Obstetrics and Gynecology Drugs Market Share by Players (2020-2025)

Table 16. Global Top Obstetrics and Gynecology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Obstetrics and Gynecology Drugs as of 2024)

Table 17. Ranking of Global Top Obstetrics and Gynecology Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Obstetrics and Gynecology Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Obstetrics and Gynecology Drugs, Headquarters and Area Served

Table 20. Global Key Players of Obstetrics and Gynecology Drugs, Product and Application

Table 21. Global Key Players of Obstetrics and Gynecology Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Obstetrics and Gynecology Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Obstetrics and Gynecology Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Obstetrics and Gynecology Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2020-2025)

Table 29. Global Obstetrics and Gynecology Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2026-2031)

Table 31. North America Obstetrics and Gynecology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Obstetrics and Gynecology Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Obstetrics and Gynecology Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Obstetrics and Gynecology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Obstetrics and Gynecology Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Obstetrics and Gynecology Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Obstetrics and Gynecology Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Obstetrics and Gynecology Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Obstetrics and Gynecology Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Obstetrics and Gynecology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Obstetrics and Gynecology Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Obstetrics and Gynecology Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Obstetrics and Gynecology Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Obstetrics and Gynecology Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. Pfizer Company Details

Table 47. Pfizer Business Overview

Table 48. Pfizer Obstetrics and Gynecology Drugs Product

Table 49. Pfizer Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 50. Pfizer Recent Development

Table 51. Merck Company Details

Table 52. Merck Business Overview

Table 53. Merck Obstetrics and Gynecology Drugs Product

Table 54. Merck Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 55. Merck Recent Development

Table 56. Eli Lilly Company Details

Table 57. Eli Lilly Business Overview

Table 58. Eli Lilly Obstetrics and Gynecology Drugs Product

Table 59. Eli Lilly Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 60. Eli Lilly Recent Development

Table 61. Amgen Company Details

Table 62. Amgen Business Overview

Table 63. Amgen Obstetrics and Gynecology Drugs Product

Table 64. Amgen Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 65. Amgen Recent Development

Table 66. Roche Company Details

Table 67. Roche Business Overview

Table 68. Roche Obstetrics and Gynecology Drugs Product

Table 69. Roche Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 70. Roche Recent Development

Table 71. AstraZeneca Company Details

Table 72. AstraZeneca Business Overview

Table 73. AstraZeneca Obstetrics and Gynecology Drugs Product

Table 74. AstraZeneca Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 75. AstraZeneca Recent Development

Table 76. Bayer Company Details

Table 77. Bayer Business Overview

Table 78. Bayer Obstetrics and Gynecology Drugs Product

Table 79. Bayer Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 80. Bayer Recent Development

Table 81. Abbott Company Details

Table 82. Abbott Business Overview

Table 83. Abbott Obstetrics and Gynecology Drugs Product

Table 84. Abbott Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 85. Abbott Recent Development

Table 86. Abbvie Company Details

Table 87. Abbvie Business Overview

Table 88. Abbvie Obstetrics and Gynecology Drugs Product

Table 89. Abbvie Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 90. Abbvie Recent Development

Table 91. GlaxoSmithKline Company Details

Table 92. GlaxoSmithKline Business Overview

Table 93. GlaxoSmithKline Obstetrics and Gynecology Drugs Product

Table 94. GlaxoSmithKline Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 95. GlaxoSmithKline Recent Development

Table 96. Novartis Company Details

Table 97. Novartis Business Overview

Table 98. Novartis Obstetrics and Gynecology Drugs Product

Table 99. Novartis Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 100. Novartis Recent Development

Table 101. Lupin Company Details

Table 102. Lupin Business Overview

Table 103. Lupin Obstetrics and Gynecology Drugs Product

Table 104. Lupin Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 105. Lupin Recent Development

Table 106. Johnson & Johnson Company Details

Table 107. Johnson & Johnson Business Overview

Table 108. Johnson & Johnson Obstetrics and Gynecology Drugs Product

Table 109. Johnson & Johnson Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 110. Johnson & Johnson Recent Development

Table 111. Ferring Company Details

Table 112. Ferring Business Overview

Table 113. Ferring Obstetrics and Gynecology Drugs Product

Table 114. Ferring Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 115. Ferring Recent Development

Table 116. TherapeuticsMD Company Details

Table 117. TherapeuticsMD Business Overview

Table 118. TherapeuticsMD Obstetrics and Gynecology Drugs Product

Table 119. TherapeuticsMD Revenue in Obstetrics and Gynecology Drugs Business (2020-2025) & (US$ Million)

Table 120. TherapeuticsMD Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Obstetrics and Gynecology Drugs Picture

Figure 2. Global Obstetrics and Gynecology Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Obstetrics and Gynecology Drugs Market Share by Type: 2024 VS 2031

Figure 4. Hormonal Therapy Features

Figure 5. Non-Hormonal Therapy Features

Figure 6. Global Obstetrics and Gynecology Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Obstetrics and Gynecology Drugs Market Share by Application: 2024 VS 2031

Figure 8. Hospital Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Online Pharmacies Case Studies

Figure 11. Obstetrics and Gynecology Drugs Report Years Considered

Figure 12. Global Obstetrics and Gynecology Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Obstetrics and Gynecology Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Obstetrics and Gynecology Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global Obstetrics and Gynecology Drugs Market Share by Players in 2024

Figure 16. Global Top Obstetrics and Gynecology Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Obstetrics and Gynecology Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Obstetrics and Gynecology Drugs Revenue in 2024

Figure 18. North America Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Obstetrics and Gynecology Drugs Market Share by Country (2020-2031)

Figure 20. United States Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Obstetrics and Gynecology Drugs Market Share by Country (2020-2031)

Figure 24. Germany Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Obstetrics and Gynecology Drugs Market Share by Region (2020-2031)

Figure 32. China Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Obstetrics and Gynecology Drugs Market Share by Country (2020-2031)

Figure 40. Mexico Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Obstetrics and Gynecology Drugs Market Share by Country (2020-2031)

Figure 44. Turkey Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Obstetrics and Gynecology Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Pfizer Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 48. Merck Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 49. Eli Lilly Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 50. Amgen Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 51. Roche Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 52. AstraZeneca Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 53. Bayer Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 54. Abbott Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 55. Abbvie Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 56. GlaxoSmithKline Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 57. Novartis Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 58. Lupin Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 59. Johnson & Johnson Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 60. Ferring Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 61. TherapeuticsMD Revenue Growth Rate in Obstetrics and Gynecology Drugs Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions